JPMorgan Slashes Upstream Bio Price Target to $8, Downgrades Stock

JPMorgan significantly cut its price target on Upstream Bio, Inc. (NASDAQ:UPB) to $8 from $35 on June 12, while downgrading the stock from Overweight to Neutral. The revision comes after the stock was previously considered one of the best low-priced stocks to get rich in 2026.

Rating Change

• Previous Rating: Overweight
• New Rating: Neutral
• Previous Price Target: $35
• New Price Target: $8

Analyst Rationale

In a research note, the analyst stated that competing drugs in the asthma space are pressuring Upstream Bio's growth prospects. No further details were provided on the exact reasons for the sharp cut.

Context

The revision comes amid high volatility in small-cap biotech valuations. No other analysts have issued similar comments yet. UPB was previously highlighted as a low-priced stock with potential for high returns, but the downgrade weakens that narrative.

What to Make of It

The JPMorgan downgrade reflects a more cautious near-term outlook for the company given rising competition. Investors are advised to weigh competitive risks before making decisions.